Contact

Even Orchard 65 Home About Services Interaction Risks Clinical Considerations FAQ & Resources Contact Independent risk context Ibogaine And Buprenorphine: Interaction Risks Combining or closely sequencing ibogaine and buprenorphine should be treated as high-risk and insufficiently studied—not as a proven detox bridge. This page is for risk understanding, not a dose, stopping plan, or individualized washout instruction. Urgent symptoms such as fainting, chest pain, severe confusion, or breathing difficulty need emergency care. Risk clarity first: cardiac, respiratory, withdrawal, and relapse concerns deserve careful review. The core concern Why this combination needs more than a simple timeline Ibogaine and buprenorphine can create overlapping concerns involving the central nervous system, opioid receptors, metabolism, and the cardiovascular system. The evidence does not establish that this is a safe combination or that a fixed number of abstinence days works for every person. Buprenorphine is an evidence-based medication for opioid dependence and substance use disorder when appropriately prescribed. It can reduce cravings and withdrawal symptoms, while abrupt discontinuation can remove overdose protection and increase vulnerability to illicit substances. The SAMHSA overview of medications for substance use disorders describes medication-assisted treatment as a recognized part of care rather than a failure to recover. 01 Cardiac uncertainty Ibogaine and noribogaine can contribute to QT prolongation, a change that may create conditions for dangerous cardiac arrhythmias. 02 Withdrawal pressure Strong receptor binding and a long half-life make buprenorphine transitions difficult to predict, especially during opioid withdrawal. 03 Monitoring limits Product purity, dose, other medications, pre-existing conditions, and emergency capability all shape patient safety. Pharmacology Understanding buprenorphine's role in opioid dependence treatment Buprenorphine is a partial

Contact

How to reach this resource